{"id":"ricrolin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a Phase 3 investigational drug from the Icahn School of Medicine at Mount Sinai, Ricrolin+ is being evaluated for efficacy and safety in its target indication. The specific molecular mechanism and target have not been widely disclosed in public literature, limiting detailed mechanistic characterization at this stage of development.","oneSentence":"Ricrolin+ is a therapeutic candidate developed at Mount Sinai that targets specific molecular pathways relevant to its indication, though the exact mechanism requires further clarification from clinical trial data.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:32:08.215Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04427956","phase":"PHASE4","title":"Corneal Crosslinking Treatment Study","status":"COMPLETED","sponsor":"Region Skane","startDate":"2017-05-23","conditions":"Progressive Keratoconus","enrollment":54},{"nctId":"NCT02117999","phase":"NA","title":"Transepithelial Corneal Cross-linking Using Iontophoresis","status":"COMPLETED","sponsor":"Fondazione G.B. Bietti, IRCCS","startDate":"2014-01","conditions":"Progressive Keratoconus","enrollment":30},{"nctId":"NCT03858036","phase":"PHASE3","title":"Corneal Collagen Cross-Linking (CXL) Performed With \"Epi-ON\" Versus \"Epi-OFF\" in Eyes With Keratoconus and Other Corneal Ectatic Disorders","status":"UNKNOWN","sponsor":"Center for Sight, Sacramento, CA","startDate":"2019-03-08","conditions":"Keratoconus, Ectasia","enrollment":550},{"nctId":"NCT03080077","phase":"PHASE3","title":"Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia","status":"UNKNOWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-06","conditions":"Keratoconus, Ectasia","enrollment":8},{"nctId":"NCT02088970","phase":"NA","title":"Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2014-09","conditions":"Bacterial Keratitis, Fungal Keratitis","enrollment":21},{"nctId":"NCT02349165","phase":"NA","title":"Standard Versus Transepithelial Corneal Crosslinking","status":"COMPLETED","sponsor":"Nienke Soeters","startDate":"2011-05","conditions":"Keratoconus","enrollment":61},{"nctId":"NCT00777322","phase":"NA","title":"T-Cat Laser & Cross-linking for Keratoconus","status":"COMPLETED","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","startDate":"2008-10","conditions":"Keratoconus, Pellucid Marginal Degeneration","enrollment":15},{"nctId":"NCT00841386","phase":"PHASE2, PHASE3","title":"Treatment of Keratoconus Using Collagen Cross-Linking","status":"UNKNOWN","sponsor":"University at Buffalo","startDate":"2008-09","conditions":"Keratoconus","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Epi-on (iontophoresis)"],"phase":"phase_3","status":"active","brandName":"Ricrolin+","genericName":"Ricrolin+","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}